Tools
Stock profile

IDEXX LABORATORIES INC /DE (IDXX)

IDXX · Latest close $698.47 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$698.47
As of Nov 18, 2026
Tracked funds holding
8 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
4
vs previous quarter

IDEXX LABORATORIES INC /DE (IDXX) is held by 8 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $28.6M sold). Latest close $698.47 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 4, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-28.6M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Fundsmith · Montrusco Bolton Investments · Polen Capital Management — 8 tracked funds hold IDXX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 22 sales ($28.6M). Insider trading

Often held alongside

CHURCH & DWIGHT CO INC /DE/ (CHD) · IDEX CORP /DE/ (IEX) · AUTOMATIC DATA PROCESSING INC (ADP) · 3M CO (MMM) · STRYKER CORP (SYK) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Fundsmith3.93%1,019,887TRIMMED (-30.4%) Q3 filed Nov 16
Montrusco Bolton Investments3.04%372,788ADDED (+9.0%) Q3 filed Oct 13
Polen Capital Management2.41%532,384TRIMMED (-23.5%) Q3 filed Nov 13
Jensen Investment Management1.35%105,709ADDED (+2861.0%) Q3 filed Nov 10
Weitz Investment Management1.29%35,300HELD Q3 filed Nov 12
Flossbach von Storch0.04%17,270TRIMMED (-4.2%) Q3 filed Oct 28
Mairs & Power Funds0.01%2,080HELD Q3 filed Nov 16
Oakmark Funds<0.01%455TRIMMED (-5.6%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +28.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

766.68344.812024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,285 of 8,857 filers
Long-only filers among them1,284
Change vs 2026 Q1no net change · 1,096 entered · 1,096 exited
Shares reported, all filers73,107,956
Reported value, all filers$37.6B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryIn Vitro & In Vivo Diagnostic Substances (SIC 2835)
Revenue · FY2025$4.3B
Net income · FY2025$1.1B
Total assets · FY2025$3.4B
Shares outstanding78,781,116
Market cap (at latest close)$55.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20261,929,268
Share of shares outstanding2.45%
Days to cover3.62

Shares short at recent settlements — Jul 31, 2026: 1.9M · Aug 14, 2026: 1.9M · Aug 31, 2026: 2.1M · Sep 15, 2026: 1.9M · Sep 30, 2026: 1.9M · Oct 15, 2026: 1.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 22 sales by 5 insiders ($28.6M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 4, 2026Underberg Sharon E.EVP, GC & Corporate SecretarySell6,348$688.25$4.4MSEC filing
Nov 4, 2026Underberg Sharon E.EVP, GC & Corporate SecretarySell1,503$689.05$1.0MSEC filing
Nov 4, 2026Underberg Sharon E.EVP, GC & Corporate SecretarySell1,055$690.02$728.0KSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell1,945$698.26$1.4MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell4,075$699.33$2.8MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell1,667$700.33$1.2MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell4,540$701.36$3.2MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell2,136$702.21$1.5MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell3,950$703.45$2.8MSEC filing
Nov 4, 2026MAZELSKY JONATHAN JAYExecutive Chair of the BoardSell240$705.59$169.3KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 4, 2026LAWRENCE D KINGSLEYDirector2,203$1.2MSep 4, 2026SEC filing
May 20, 2026Margaret Anne SzostakDirector1,344$744.0KMay 20, 2026SEC filing
Mar 3, 2026NIMRATA K HUNTOfficer1,758$1.1MMar 3, 2026SEC filing
Feb 26, 2026JONATHAN J MAZELSKYOfficer, Director23,326$15.3MFeb 26, 2026SEC filing
Feb 25, 2026NIMRATA K HUNTOfficer2,693$1.8MFeb 25, 2026SEC filing
Feb 17, 2026SOPHIE V VANDEBROEKDirector1,464$920.3KFeb 17, 2026SEC filing
Feb 17, 2026MICHAEL G ERICKSONOfficer5,371$3.4MFeb 17, 2026SEC filing
Feb 10, 2026GEORGE FENNELLOfficer11,345$7.3MFeb 10, 2026SEC filing
Nov 7, 2025NIMRATA K HUNTOfficer9,425$6.6MNov 7, 2025SEC filing
Aug 22, 2025MARGARET ANNE SZOSTAKDirector2,187$1.4MAug 22, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 30, 2026Vanguard Capital ManagementSC 13G5,976,4727.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A7,599,0789.4%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Growth — Revenue up every year for 5 straight years

· Piotroski — Financial health improved over the past year

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Buffett — Latest ROE: 56.9% · Years ROE ≥15% (of 10): 10 · 10-yr avg ROE: 88.2% · Latest net income: $845.0M

· Growth — Latest revenue: $4.3B · 5-yr revenue CAGR: 9.7% · Straight growth years: 9

· Piotroski — F-score: 7 · Return on assets: 31.6% · Operating cash flow: $1.2B

· Gross Profitability (Novy-Marx) — Gross profit / assets: 79.4% · Gross margin: 61.8%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.08 · Operating cash flow: $1.2B · Net income: $1.1B

· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $1.1B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q2, ranked #32 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together742.9%-1.1%+3.3%-4.5%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold IDXX — ranked by lift, the co-holding pattern described in Methodology: CHURCH & DWIGHT CO INC /DE/ (CHD) · IDEX CORP /DE/ (IEX) · AUTOMATIC DATA PROCESSING INC (ADP) · 3M CO (MMM) · STRYKER CORP (SYK) · VANGUARD MRNGSTAR GR ETF-SUI (VUG) · Zoetis Inc. (ZTS) · MARSH & MCLENNAN COMPANIES, INC. (MRSH).

Filings audit: every filing lens on IDEXX LABORATORIES INC /DE (IDXX), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
May 15, 20265.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

CHURCH & DWIGHT CO INC /DE/ (CHD) · Filings audit: every filing lens on IDEXX LABORATORIES INC /DE (IDXX), scored · Practice timing on IDXX

One email a week: the week’s new filings and research. Subscribe free

← IDT  ·  IDYA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.